Radioactive iodine (RAI) treatment of hyperthyroidism is safe in patients with Graves' orbitopathy - A prospective study

Endokrynologia Polska

Volumn 65, Issue 1, 2014, Pages 40-45

  Król, Aleksandra ^a   Koehler, Aleksandra ^a   Nowak, Mariusz ^b   Paliczka Cieślik, Ewa ^a   Krajewska, Jolanta ^a   Kalemba, Michał ^a   Jurecka Lubieniecka, Beata ^a   Hasse Lazar, Kornelia ^a   Michalik, Barbara ^a   Szpak Ulczok, Sylwia ^a   Zarudzki, Łukasz ^c   Roskosz, Józef ^a   Jarza̧b, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Glucocorticosteroid prophylaxis; Graves' orbitopathy

Indexed keywords

EYE DROPS; IODINE 131; PREDNISONE; ANTITHYROID AGENT; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; EXTRAOCULAR MUSCLE; FEMALE; FOLLOW UP; GRAVES DISEASE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MUSCLE THICKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RADIATION DOSE; RISK FACTOR; SMOKING; SYMPTOM; THYROID SURGERY; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; COMORBIDITY; GRAVES OPHTHALMOPATHY; HYPERTHYROIDISM;

ADOLESCENT; ADULT; AGED; ANTITHYROID AGENTS; COMORBIDITY; DISEASE PROGRESSION; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84896702843     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2014.0006     Document Type: Article

References (24)

1. Solomon B, Glinoer D, Lagasse R et al. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990; 70: 1518-1524.
2. Bartalena L, Tanda ML, Piantanida E et al. Relationship between management of hyperthyroidism and course of the ophtalmopathy. J Endocrinol Invest 2004; 27: 288-294.
3. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid 2010; 20: 785-793.
4. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-78.
5. Tallstedt L, Lundell G, Tørring O et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326: 1733-8
6. Marcocci C, Bartalena L, Bogazzi F et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 473-478.
7. Bartalena L, Marcocci C, Bogazzi F et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-1352.
8. Bartalena L, Marcocci C, Tanda ML et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998; 129: 632-635.
9. Marcocci C, Bartalena L, Tanda ML et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86: 3562-3567.
10. Laurberg P, Wallin G, Tallstedt L et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75.
11. Eckstein AK, Plicht M, Lax H et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470.
12. Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994; 79: 542-546.
13. Wall JR, Lahooti H. Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol 2010; 61: 222-227.
14. Sawicka N, Sowinski J. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease Endokrynol Pol 2012; 63: 10-13.
15. Bednarczuk T., Bar-Andziak E., Hubalewska-Dydejczyk A et al. Management of Graves' orbitopathy. Comments on EUGOGO consensus statement. Endokrynol Pol 2009; 60: 312-330.
16. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy, Clin Endocrinol (Oxf) 1995; 42: 45-50.
17. Lowery AJ, Kerin MJ. Graves' ophthalmopathy: the case for thyroid surgery. Surgeon 2009; 7: 290-296.
18. Stålberg P, Svensson A, Hessman O et al. Surgical treatment of Graves' disease: evidence-based approach. World J Surg 2008; 32: 1269-1277.
19. Manso PG, Furlanetto RP, Wolosker AM et al. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism. Thyroid 1998; 8: 49-52.
20. Bartalena L. Editorial: glucocorticoids for Graves' ophthalmopathy: how and when. J Clin Endocrinol Metab 2005; 90: 5497-5499.
21. Bartalena L, Tanda ML, Piantanida E et al. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005; 153: 13-14.
22. Vannucchi G, Campi I, Covelli D et al. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009; 94: 3381-3386.
23. Wiersinga WM. Management of Graves' ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007; 3: 396-404.
24. Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011; 96: 592-599.